Galapagos jumps on collaboration with Blood Centers of America

Lakefront Biotherapeutics NV

16/05/2024 08:48

** Shares in Galapagos  GLPG.AS  rise about 3%, after the
Belgium-based drugmaker announced a collaboration with Blood
Centers of America (BCA)
    ** This collaboration gives Galapagos access to BCA's
network of over 50 sites in the U.S. for the decentralised
manufacturing (POC) of its chimeric antigen receptor T (CAR-T)
cell therapies, the company says
    ** "We believe this collaboration could unlock significant
manufacturing capacity for Galapagos in the U.S.," says KBC
Securities
    ** "Our back of the envelope calculation points to a
capacity of 8K CAR-Ts per year with just 4 Cocoon's in each
site," adds KBC
    ** The brokerage ups Galapagos to "buy" from "accumulate",
pointing to "a big step towards demonstrating the scalability of
Galapagos' decentralised manufacturing model"
    ** Stock is top performer on BEL 20 index  .BFX 

 (Reporting by Clement Martinot)
 ((Clement.martinot@tr.com))